The effects of a chemical defense pretreatment drug. pyridostigmine bromide (PB). on in-flight aircrew performance were assessed using the Total In-Flight Simulator (TIFS) aircraft. TIFS was used to supply appropriate control dynamics, handling characteristics, and cockpit instrumentation for a tactical transport airdrop simulation. Twenty-one C-130 pilots flew two familiarization and four data flights. During two data flights PB was given to both members of the aircrew using the dosage regimen of 30 mg/8 h prescribed by the U.S. Air Force surgeon general. The drug was administered using a double-blind technique. The results indicated that (1) aircrews successfully completed their assigned mission, (2) airdrop inaccuracies and navigation errors in time and distance were not specifically related to PB, (3) performance and crew coordination were not affected by PB, (4) PB and pilot/copilot order significantly affected copilot tasks, and (5) subjects and observers did not discriminate beyond chance between PB and placebo conditions.
Get full access to this article
View all access options for this article.
References
1.
Aquilonius, S. M., Eckernas, S. A., Hartvig, P., Lindstrom, B., and Osterman, P. O. (1980). Pharmacokinetics and oral bioavailability of pyridostigmine in man. European Journal of Clinical Phannacology, 18, 423–428.
2.
Borland, R. G., Brenna, D. H., Nicholson, A. N., and Smith, P. A. (1985). Studies on the possible central and peripheral effects in man of a cholinesterase inhibitor (pyridostigmine). Human Toxicology, 4, 293–300.
3.
Dirnhuber, P., and Green, D. M. (1978). Effectiveness of pyridostigmine bromide in reversing neuromuscular blockage produced by soman. Journal of Pharmacy and Pharmacology, 30, 419–425.
4.
French, H. C., Wetherall, J. R., and White, P. D. T. (1979). The reversal by pyridostigmine of neuromuscular block produced by soman. Journal of Pharmacy and Pharmacology, 31, 290–294.
5.
Gall, D. (1981). The use of therapeutic mixtures in the treatment of cholinesterase inhibition. Fundamental Applied Toxicology, 1, 214–216.
6.
Gawron, V. J., Knotts, L. H., and Schiflett, S. G. (1989). Mapping laboratory tests to in-flight tasks. In Proceedings of the American Institute of Aeronautics and Astronautics Flight Simulation Conference (pp. 462–469). Washington, DC: AIAA.
7.
Graham, C., and Cook, M. R. (1984). Effects of pyridostigmine on psychomotor and visual performance (Tech. Report AFAMRL-TR-84-052). Wright-Patterson Air Force Base, OH: Armstrong Aerospace Medical Research Laboratory.
8.
Grob, D., and Johns, R. J. (1958). Treatment of anticholinesterase intoxication with oximes: Use in normal subjects and in patients with myasthenia gravis. Journal of the American Medical Association, 166, 1855–1858.
9.
Kay, C. D., and Morrison, J. D. (1985). The effects of a single oral dose of pyridostigmine on contrast sensitivity. Glasgow: University of Glasgow, Institute of Physiology.
10.
Kirk, R. E. (1968). Experimental design: Procedures for the behavioral sciences. Belmont, CA: Brooks/Cole.
11.
Krutz, R., Burton, R., Holden, R., Fischer, J., and DeCarlis, J. (1987, May). Physiologic effects of pyridostigmine bromide at ground level and altitude. Paper presented at the Aerospace Medical Association Annual Meeting, Las Vegas, NV.
12.
Lipp, J., and Dola, T. (1980). Comparison of the efficacy of HS-6 versus HI-6 when combined in atropine, pyridostigmine, and clonazepam for soman poisoning in the monkey. Archives of Internal Pharmacodynamic, 246, 138–148.
13.
Long, G., and Marsh, H. M. (1981). The effect on heart rate of neuromuscular blockade reversal by pyridostigmine. Anaesthesia Intensive Care, 9, 144–146.
14.
Melander, A. (1978). Influence of food on the bioavailability of drug. Clinical Pharmacokinetics, 3, 337–351.
15.
Mirakhur, R. K., Briggs, L. P., Clarke, R. S. J., Dundee, J. W., and Johnston, H. M. L. (1981). Comparison of atropine and glycopyrolate in a mixture with pyridostymine for the antagonism of neuromuscular block. British Journal of Anaesthesia, 53, 1315–1319.
16.
Morris, T. L. (1985). Electro-oculographic indices of changes in simulated flying performance. Behavioral Research Methods, Instruments, and Computers, 17, 176–182.
17.
Perez, W. A., Masline, P. J., Ramsey, E. G., and Urban, K. E. (1987). Unified tri-service cognitive performance assessment battery: Review and methodology (Tech. Report AAMRL-TR-87-007). Wright-Patterson Air Force Base, OH: Armstrong Aerospace Medical Research Laboratory.
18.
Physician's desk reference. (1990). Oradell, NJ: Medical Economics Company.
19.
Schiflett, S., Stranges, S., Slater, T., and Jackson, M. (1987, May). The effects of pyridostigmine bromide on performance at ground level and altitude. Paper presented at the Aerospace Medical Association Annual Meeting, Las Vegas, NV.
20.
Somani, S. M., Roberts, J. B., and Wilson, A. (1972). Pyridostigmine metabolism in man. Clinical Phannacology Therapy, 13, 393–399.
21.
Stitcher, D. L., Harris, L. W., Heyl, W. C., and Alter, S. C. (1978). Effects of pyridostigmine and cholinolytics on cholinesterase and acetylcholine in soman. Drug Chemical Toxicology, 1, 335–378.
22.
Whinnery, J. E. (1985a). Flight testing of pyridostigmine bromide in the tactical fighter aircraft environment. Kelly Air Force Base, TX: Texas Air National Guard, 182nd Tactical Fighter Squadron.
23.
Whinnery, J. E. (1985b). Pyridostigmine bromide: A preexposure antidote for specific chemical warfare nerve agents. A condensed review for the aeromedical specialist (Tech. Report USAFSAM-TR-85–15). Brooks Air Force Base, TX: School of Aerospace Medicine.
24.
Williams, J. I. (1984). Human response to pyridostigmine bromide (ARAMRL-TR-84-004). Brooks Air Force Base, TX: Aerospace Medical Research Laboratory.
